Abstract Library

#2954 Aggressive Resection - A Treatment Option in Patients with Advanced Neuroendocrine Tumors

Introduction: Different treatment modalities have been considered for patients with malignant advanced neuroendocrine tumors(NETs) of the pancreas and duodenum.Aggressive surgery remains a controversial yet an efficacious antitumor therapy.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Athar A,

Keywords: Surgical resection, Advanced NET,

#2871 Increase of Ki-67 Index over Time and Influence on All-Cause Mortality in Patients with Neuroendocrine Neoplasms (NEN)

Introduction: Increase of Ki-67 index in NEN over time in relation to progression and a potential influence on prognosis is scarcely studied.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Holmager P

Authors: Holmager P, Langer S, Federspiel B, Willemoe G, Garbyal R,

Keywords: Ki-67 index, Prognosis, Mortality,

#2833 Surgical Correction of Carcinoid Heart Disease Improves Liver Function and 5-Hydroxyindoleacetic Acid Levels

Introduction: Neuroendocrine tumours of the gastrointestinal tract cause carcinoid syndrome and carcinoid heart disease. These tumours secrete serotonin, which can bind to heart valves and cause fibrosis and valve incompetence. Most cases involve the tricuspid valve +/- pulmonary valve. Medical management comprises diuretics for fluid overload and somatostatin analogues to reduce circulating serotonin. Definitive treatment is heart-valve replacement surgery which improves exercise tolerance but has high perioperative mortality. We have previously reported that valve-replacement surgery can reduce 5-hydroxyindoleacetic acid (5-HIAA) levels, reflecting a decline in hormone activity.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Shah H

Authors: Shah H, Sagar V, Venkataraman H, Steeds R, Rooney S,

Keywords: carcinoid, carcinoid syndrome, neuroendocrine tumour, carcinoid heart disease, 5hiaa,

#2243 Somatostatin Analogs (SSAs) as Effective Treatment of Resectable, non Metastatic, non Functioning Pancreatic Neuroendocrine Tumors (NF-pNETs) in Patients Unfit for Surgery. A Case Series.

Introduction: SSAs are used to treat symptomatic functioning pNETs and to prolong progression free survival in metastatic, G1/G2, somatostatin receptor-positive pNETs. Pancreatic surgery is burdened with important morbidity and mortality, especially in patients with increased anaesthesiological risk.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Nessi C, Paiella S, Miotto M, Viviani E, Zingaretti C,

Keywords: somatostatin analogs, resectable pnets,

#2204 Pancreatic Neuroendocrine Tumors: Analysis of Prognostic Factors After Surgical Resection in a Single Centre

Introduction: Pancreatic neuroendocrine tumors (PNET) are rare, heterogeneous and challenging neoplasms. Surgical resection is the only curative treatment. Recurrence can occur even after years. Diagnosis of malignancy is difficult so further studies are necessary to identify prognostic criteria.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Blanco L, Dopazo C, Pando E, Caralt M, Puértolas N,

Keywords: PNETS, Prognosis,